NASDAQ:MEDP Medpace (MEDP) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free MEDP Stock Alerts $395.93 +6.16 (+1.58%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$388.88▼$397.1750-Day Range$372.00▼$413.3152-Week Range$189.30▼$421.00Volume144,681 shsAverage Volume240,981 shsMarket Capitalization$12.27 billionP/E Ratio40.36Dividend YieldN/APrice Target$443.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Medpace alerts: Email Address Medpace MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside11.9% Upside$443.00 Price TargetShort InterestHealthy3.97% of Float Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment0.65Based on 45 Articles This WeekInsider TradingSelling Shares$76.65 M Sold Last QuarterProj. Earnings Growth16.03%From $11.23 to $13.03 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.97 out of 5 starsMedical Sector15th out of 914 stocksCommercial Physical Research Industry1st out of 10 stocks 3.4 Analyst's Opinion Consensus RatingMedpace has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMedpace has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.97% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Medpace has recently increased by 4.00%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMedpace does not currently pay a dividend.Dividend GrowthMedpace does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedpace has received a 72.85% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Medical devices engineering", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Medpace is -0.62. Previous Next 3.7 News and Social Media Coverage News SentimentMedpace has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 45 news articles for Medpace this week, compared to 7 articles on an average week.Search Interest15 people have searched for MEDP on MarketBeat in the last 30 days. This is an increase of 88% compared to the previous 30 days.MarketBeat Follows86 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is an increase of 514% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medpace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $76,651,647.00 in company stock.Percentage Held by Insiders20.30% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Medpace are expected to grow by 16.03% in the coming year, from $11.23 to $13.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medpace is 40.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.26.Price to Earnings Ratio vs. SectorThe P/E ratio of Medpace is 40.36, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 183.94.Price to Earnings Growth RatioMedpace has a PEG Ratio of 1.94. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioMedpace has a P/B Ratio of 18.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Medpace Stock (NASDAQ:MEDP)Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.Read More MEDP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEDP Stock News HeadlinesApril 27, 2024 | americanbankingnews.comEquities Analysts Set Expectations for Medpace Holdings, Inc.'s Q2 2024 Earnings (NASDAQ:MEDP)April 26, 2024 | americanbankingnews.comMedpace Holdings, Inc. (NASDAQ:MEDP) Forecasted to Post FY2024 Earnings of $11.07 Per ShareApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 26, 2024 | seekingalpha.comMedpace Holdings, Inc. (MEDP) Q1 2024 Earnings Call TranscriptApril 25, 2024 | msn.comMedpace raised to Buy at Jefferies after Q1 earnings beatApril 25, 2024 | americanbankingnews.comMedpace (NASDAQ:MEDP) Price Target Raised to $464.00 at GuggenheimApril 25, 2024 | americanbankingnews.comMedpace (NASDAQ:MEDP) Sets New 12-Month High Following Analyst UpgradeApril 24, 2024 | msn.comIBD Stock Of The Day Medpace Flirts With Breakout After Big Earnings ReversalApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 24, 2024 | finance.yahoo.comMedpace Holdings Inc (MEDP) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...April 24, 2024 | finance.yahoo.comMedpace Holdings, Inc. Just Beat EPS By 30%: Here's What Analysts Think Will Happen NextApril 24, 2024 | finance.yahoo.comMedpace Holdings, Inc. (NASDAQ:MEDP) Q1 2024 Earnings Call TranscriptApril 24, 2024 | americanbankingnews.comMedpace (NASDAQ:MEDP) Upgraded by Jefferies Financial Group to BuyApril 24, 2024 | americanbankingnews.comMedpace (NASDAQ:MEDP) Upgraded to Buy at StockNews.comApril 24, 2024 | americanbankingnews.comMedpace (NASDAQ:MEDP) Sees Unusually-High Trading Volume on Earnings BeatApril 24, 2024 | finance.yahoo.comQ1 2024 Medpace Holdings Inc Earnings CallApril 23, 2024 | markets.businessinsider.comDecoding 5 Analyst Evaluations For Medpace HldgsApril 23, 2024 | seekingalpha.comMedpace Holdings, Inc. 2024 Q1 - Results - Earnings Call PresentationApril 22, 2024 | investorplace.comMEDP Stock Earnings: Medpace Hldgs Beats EPS, Misses Revenue for Q1 2024April 22, 2024 | sfgate.comMedpace: Q1 Earnings SnapshotApril 22, 2024 | msn.comMedpace GAAP EPS of $3.20 beats by $0.73, revenue of $511M misses by $1MApril 22, 2024 | finance.yahoo.comMedpace Holdings Inc (MEDP) Surpasses Analyst Revenue and Earnings Projections in Q1 2024April 22, 2024 | businesswire.comMedpace Holdings, Inc. Reports First Quarter 2024 ResultsApril 19, 2024 | msn.comMedpace Q1 2024 Earnings PreviewApril 17, 2024 | msn.comAn iconic bar returns (and the 3 best things I ate last week)April 17, 2024 | markets.businessinsider.comMedpace Holdings Inc hosts conference call for investorsApril 11, 2024 | benzinga.comIf You Invested $1000 In This Stock 5 Years Ago, You Would Have $6,800 TodaySee More Headlines Receive MEDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/22/2024Today4/27/2024Next Earnings (Estimated)7/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:MEDP CUSIPN/A CIK1668397 Webwww.medpace.com Phone(513) 579-9911Fax513-579-0444Employees5,900Year FoundedN/APrice Target and Rating Average Stock Price Target$443.00 High Stock Price Target$464.00 Low Stock Price Target$395.00 Potential Upside/Downside+11.9%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$9.81 Trailing P/E Ratio40.36 Forward P/E Ratio35.26 P/E Growth1.94Net Income$282.81 million Net Margins15.92% Pretax Margin18.47% Return on Equity59.74% Return on Assets19.70% Debt Debt-to-Equity RatioN/A Current Ratio0.78 Quick Ratio0.64 Sales & Book Value Annual Sales$1.89 billion Price / Sales6.50 Cash Flow$10.23 per share Price / Cash Flow38.69 Book Value$21.67 per share Price / Book18.27Miscellaneous Outstanding Shares30,980,000Free Float24,693,000Market Cap$12.27 billion OptionableOptionable Beta1.38 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. August James Troendle M.D. (Age 68)Chairman & CEO Comp: $1.68MMr. Jesse J. Geiger BBA (Age 50)CPA, President Comp: $876.92kMr. Kevin M. Brady (Age 49)CFO & Treasurer Comp: $636.58kMs. Susan E. Burwig BSN (Age 61)MA, Executive Vice President of Operations Comp: $1MMr. Stephen P. Ewald J.D. (Age 55)Chief Compliance Officer, General Counsel & Corporate Secretary Comp: $826.17kBrandon EbkenChief Information OfficerMs. Lauren MorrisAssociate Director of Investors RelationsMr. Todd MeyersVice President of Business Development & MarketingJohn T. Wynne MBASenior Vice President of Commercial Operations & Clinical Pharmacology UnitMr. Reinilde Heyrman M.D. (Age 63)Chief Medical Officer of Medical Department More ExecutivesKey CompetitorsCharles River Laboratories InternationalNYSE:CRLIncyteNASDAQ:INCYPRA Health SciencesNASDAQ:PRAHLaboratory Co. of AmericaNYSE:LHExelixisNASDAQ:EXELView All CompetitorsInsiders & InstitutionsRiverbridge Partners LLCSold 77,693 shares on 4/26/2024Ownership: 1.957%McGuire Investment Group LLCBought 239 shares on 4/26/2024Ownership: 0.145%Yousif Capital Management LLCSold 432 shares on 4/26/2024Ownership: 0.035%UMB Bank n.a.Sold 177 shares on 4/26/2024Ownership: 0.000%Zurcher Kantonalbank Zurich Cantonalbank Sold 371 shares on 4/25/2024Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions MEDP Stock Analysis - Frequently Asked Questions Should I buy or sell Medpace stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MEDP shares. View MEDP analyst ratings or view top-rated stocks. What is Medpace's stock price target for 2024? 5 analysts have issued 1 year price objectives for Medpace's stock. Their MEDP share price targets range from $395.00 to $464.00. On average, they predict the company's stock price to reach $443.00 in the next year. This suggests a possible upside of 11.9% from the stock's current price. View analysts price targets for MEDP or view top-rated stocks among Wall Street analysts. How have MEDP shares performed in 2024? Medpace's stock was trading at $306.53 at the beginning of the year. Since then, MEDP stock has increased by 29.2% and is now trading at $395.93. View the best growth stocks for 2024 here. When is Medpace's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 22nd 2024. View our MEDP earnings forecast. How were Medpace's earnings last quarter? Medpace Holdings, Inc. (NASDAQ:MEDP) issued its earnings results on Monday, April, 22nd. The company reported $3.20 EPS for the quarter, beating the consensus estimate of $2.45 by $0.75. The company earned $511 million during the quarter, compared to analyst estimates of $512.39 million. Medpace had a trailing twelve-month return on equity of 59.74% and a net margin of 15.92%. The company's revenue for the quarter was up 17.7% on a year-over-year basis. During the same period in the previous year, the firm earned $2.27 earnings per share. What ETFs hold Medpace's stock? ETFs with the largest weight of Medpace (NASDAQ:MEDP) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Congress SMid Growth ETF (CSMD), Argent Mid Cap ETF (AMID), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Invesco S&P MidCap Quality ETF (XMHQ), First Trust Health Care AlphaDEX Fund (FXH) and Alpha Architect U.S. Quantitative Momentum ETF (QMOM). What guidance has Medpace issued on next quarter's earnings? Medpace issued an update on its FY 2024 earnings guidance on Monday, April, 22nd. The company provided earnings per share guidance of 10.790-11.470 for the period, compared to the consensus estimate of 10.610. The company issued revenue guidance of $2.2 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion. What is August Troendle's approval rating as Medpace's CEO? 268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Medpace own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG). When did Medpace IPO? Medpace (MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers. Who are Medpace's major shareholders? Medpace's stock is owned by a number of retail and institutional investors. Top institutional investors include Wasatch Advisors LP (3.15%), Riverbridge Partners LLC (1.96%), Los Angeles Capital Management LLC (0.85%), Congress Asset Management Co. MA (0.50%), Rice Hall James & Associates LLC (0.39%) and Assenagon Asset Management S.A. (0.35%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Robert O Kraft, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc. View institutional ownership trends. How do I buy shares of Medpace? Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MEDP) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithJeff Bezos Just Humiliated Elon MuskInvestorPlaceBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medpace Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
